Skip to search formSkip to main contentSkip to account menu

ACT 064992

Known as: ACT-064992, ACT064992 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Macitentan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
Effect of macitentan on hospitalizations: results from the SERAPHIN trial.
Review
2014
Review
2014
Macitentan for the Treatment of Pulmonary Arterial Hypertension
Objective: To review the pharmacology, safety, and efficacy of macitentan. Data Sources: PubMed, EMBASE, and ClinicalTrials.gov… 
2011
2011
Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human…
Potential treatments for ovarian cancers that have become resistant to standard chemotherapies include modulators of tumor cell… 
2011
2011
Abstract 601: Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic…
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Introduction: In 2009, ovarian cancer was the leading… 
2009
2009
Comparison of the dissolution and pharmacokinetic profiles of two galenical formulations of the endothelin receptor antagonist macitentan.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)